Atracurium Besylate CAS 64228-81-5

Product name:Atracurium besylate
CAS:64228-81-5
MF:C65H82N2O18S2
MW:1243.48

EINECS: 264-743-4
Melting point: 85-90°C

Purity:≥99%

White crystalline powder

1. Atracurium besylate CAS 64228-81-5 is a skeletal muscle relaxant used as an adjunct to general anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery.
2. Atracurium besylate CAS 64228-81-5 is also used in intensive care units (ICU) to facilitate mechanical ventilation and as a sedative adjunct .
3. Atracurium besylate CAS 64228-81-5 is a non-depolarizing neuromuscular blocking agent with an intermediate duration of action, and its degradation is independent of hepatic and renal function via Hofmann elimination .
4. Atracurium besylate CAS 64228-81-5 belongs to the benzylisoquinolinium class and is distinct from cisatracurium besylate, which is a single isomer with different potency and histamine-release properties .

1. Store Atracurium besylate CAS 64228-81-5 under refrigeration at 2°C to 8°C, protected from freezing and light .
2. Intact vials of Atracurium besylate CAS 64228-81-5 may be used for up to 14 days at room temperature, but decomposition increases at higher temperatures (approximately 5% per month at 25°C) .
3. Atracurium besylate CAS 64228-81-5 is unstable in acidic and alkaline conditions, with maximum stability around pH 2.5, and must not be mixed with alkaline solutions such as barbiturates .
4. Once diluted for infusion, Atracurium besylate CAS 64228-81-5 solutions should be used immediately unless prepared under aseptic conditions; stability in infusion fluids ranges from 4 to 24 hours depending on the diluent .

1. Atracurium besylate CAS 64228-81-5 can cause severe anaphylactic or anaphylactoid reactions, which in rare cases have been life-threatening or fatal .
2. Atracurium besylate CAS 64228-81-5 may cause histamine release leading to skin flushing, hypotension, tachycardia, and bronchospasm .
3. Prolonged use of Atracurium besylate CAS 64228-81-5 in ICU patients has been associated with rare reports of seizures and muscle weakness or myopathy, particularly with concomitant corticosteroid use .
4. Atracurium besylate CAS 64228-81-5 has an intravenous LD50 of 131 mg/kg in rats and is not mutagenic in bacterial or in vivo cytogenetic tests .

1. Atracurium besylate CAS 64228-81-5 is not safe for self-administration and must only be used by trained anesthesia professionals with immediate access to airway management and resuscitation equipment .
2. Atracurium besylate CAS 64228-81-5 has not been evaluated for carcinogenicity or fertility effects in animal studies, and its use in pregnancy requires careful risk-benefit assessment .
3. Atracurium besylate CAS 64228-81-5 requires appropriate personal protective equipment (nitrile gloves, safety glasses, protective clothing) during handling by healthcare personnel .
4. Atracurium besylate CAS 64228-81-5 must be disposed of as pharmaceutical hazardous waste and must not be released into drains or the environment .

1 kg/bag, 25 kg/bag, 1000 kg/bag or based on customers' requirements.

Transportation

We arrange suitable logistics schemes based on each customer's needs. Small-volume goods can be delivered via air shipment or international express services like FedEx, DHL, TNT, UPS and specialized cross-border logistics lines. For bulk orders, sea transportation can be arranged to reach your appointed port. Beyond that, we are capable of offering value-added customized logistics services considering product features and specific client requests.

Payment

 

To facilitate smooth cooperation,we offers multiple flexible settlement solutions for clients. Small orders can be settled via PayPal, Western union. For substantial orders, we adopt T/T, L/C at sight. Furthermore, Alipay and WeChat pay have become popular payment choices among our customers.

 

 

 

 

 

Customer Visit

 

 

Customer Trust